U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H20N2O4S2
Molecular Weight 392.492
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PESAMPATOR

SMILES

CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N

InChI

InChIKey=TTYKUKSFWHEBLI-DLBZAZTESA-N
InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H20N2O4S2
Molecular Weight 392.492
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

PF-04958242 is an AMPA receptor potentiator for the potential treatment of cognitive deficits in schizophrenia. But recent study revealed that there were no pharmacokinetic interactions between PF-04958242 and ketamine. 'High-impact' AMPAR potentiators like PF-04958242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia. In addition, a clinical study was underway to evaluate the effects of PF-049582432 in subjects with age-related hearing loss in the US. PF-04958242 has been classified as glycine transporter (GLYT-1) inhibitor in this study. However, this development was discontinued.

Originator

Approval Year

PubMed

Substance Class Chemical
Record UNII
9G1A824CC2
Record Status Validated (UNII)
Record Version